1 / 4

Pulmonary Arterial Hypertension (PAH) Market

Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs.

deepakraj
Télécharger la présentation

Pulmonary Arterial Hypertension (PAH) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pulmonary Arterial Hypertension (PAH) Market Outlook 2028 The global pulmonary arterial hypertension (PAH) market was valued at US$ 5.2 Bn in 2020 It is estimated to expand at a CAGR of 5.4% from 2021 to 2028 The global pulmonary arterial hypertension (PAH) market is expected to reach the value of US$ 13.5 Bn by the end of 2028    Report Overview:https://www.transparencymarketresearch.com/pulmonary- arterial-hypertension-therapeutics.html Increase in Awareness about Pulmonary Arterial Hypertension Pulmonary arterial hypertension (PAH) is a rare and progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH occurs when pulmonary arteries become narrow in diameter or get blocked. In the past few years, there has been an increasing prevalence of PAH disorder due to rising risk factors such as HIV, sedentary lifestyle, tobacco and alcohol consumption, smoking, and other idiopathic conditions. There are high- growth opportunities for market players in the near future due to increasing prevalence of PAH across the globe. Various treatments are available in the market that helps in controlling and slowing down the growth of the diseases and improving the quality of life. In addition, the approval of few effective drugs and the occurrence of favorable pipeline are some of primary factors that drive the global market. Moreover, favorable policies by government has contributed in boosting the demand in the global pulmonary arterial hypertension market. Rapid Growth in Geriatric Population to Fuel Market Expansion The increase in geriatric population in developing countries is expected to drive the global pulmonary arterial hypertension market in the upcoming years. The rising incidence of PAH in the geriatric population is driving the global pulmonary arterial hypertension market during the forecast period. Aging is one of the non-modifiable factors that increases the risk related to PAH. Elderly people are more susceptible to this disease due to diastolic dysfunction and age-associated blood vessel stiffening. Several educational programs have been initiated by key market contributors and governments to increase awareness about PAH among healthcare providers and patients. All these factors are expected to boost the global pulmonary arterial hypertension market over the next few years. Technological Advancements and Approval of New Drugs to Drive Global Market Technological advancements in drug discovery & development, along with rising research & development activities across the globe are driving the pulmonary arterial hypertension (PAH) market. Based on drug class, the global pulmonary arterial

  2. hypertension (PAH) market has been classified into prostacyclin & prostacyclin analogs, PDE-5 inhibitors, ERAs (endothelin receptor antagonists), and soluble guanylate cyclase (sGC) stimulators. The prostacyclin & prostacyclin analogs segment is expected to dominate the market in the near future due to high demand. The SGC simulators segment is anticipated to grow at a rapid pace during the forecast period. sGC stimulators can ensure maximum activation of sGC by potentiating NO-sGC signaling. Riociguat (Adempas from Bayer) is the only drug approved for PAH in this category. Request Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep _id=1181 Promising Drug Pipeline to Boost Market in North America Geographically, North America is projected to dominate the global pulmonary arterial hypertension (PAH) market during the forecast period. North America is followed by Europe, and the market in both regions is projected to grow remarkably throughout the forecast period. This can be ascribed to the availability of commercialization of new PAH drugs coupled with a promising drug pipeline. In addition, growing awareness among people in both regions about the rising availability of treatment for pulmonary arterial hypertension is also pushing the market growth. Moreover, Asia Pacific possess lucrative opportunities for the market players. Countries such as Japan, New Zealand, Australia, China, and India are projected to offer high growth opportunities attributing to growing penetration of global players. Pulmonary Arterial Hypertension (PAH) Market: Overview  According to Transparency Market Research’s latest report on the global pulmonary arterial hypertension (PAH) market for the historical period 2017–2019 and forecast period 2021–2028, increase in initiatives by key players, higher cases of pulmonary arterial hypertension, rise in adoption rate, availability of reimbursement, and entry of generics are projected to drive the global market during the forecast period. Increase in Collaborations for Development of Novel Products: Key Driver Focus on collaborations & mergers by leading players to develop innovative products is anticipated to boost the growth of the global market during the forecast period. In 2017, Bayer AG and Vectura Group plc extended their collaboration to develop an upgraded version of nebulizer Breelib that improves the efficacy of iloprost aerosol therapy for pulmonary atrial hypertension. According to the National Institutes of Health, the nebulizer is still in clinical trial and the study was finished in March 2020. In September 2018, United Therapeutics entered into a collaboration with MannKind Corporation for the development and commercialization of dry powder formulation of treprostinil. This research was conducted by Mannkind on behalf of United Therapeutics for products outside the scope of the licensing and collaboration agreement.   COVID-19 Impact Analysis

  3. The impact of the coronavirus outbreak on the industry peaked during early 2020, wherein pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus crisis Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain had impeded the industry expansion The pandemic has reinforced the importance of pulmonary arterial hypertension drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.    Side Effects Associated with PAH Drugs: Key Restraint Side effects associated with PAH drugs are likely to hamper the growth of the global market. Vasodilators are primarily prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels. According to studies, vasodilators have a number of side effects including edema, heart palpitations, tachycardia, and chest pain. Due to the substantial side effects associated with the use of vasodilators among chronically ill patients, the U.S. FDA regulates the use of this drug. Moreover, manufacturers of PAH drugs that treat high blood pressure and dilate blood vessels are required to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercialization. The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the usage of PAH drugs are projected to restrain the global market during the forecast period.     Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&re p_id=1181 Pulmonary Arterial Hypertension (PAH) Market: Competition Landscape This report profiles major players in the global pulmonary arterial hypertension (PAH) market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments The global pulmonary arterial hypertension (PAH) market is highly fragmented, with the presence of a number of international as well as regional players Leading players operating in the global pulmonary arterial hypertension (PAH) market are oActelion Pharmaceuticals, Ltd. oGilead Sciences, Inc. oGlaxoSmithKline plc oPfizer, Inc. oUnited Therapeutics Corporation, among others    About Transparency Market Research

  4. Transparency Market Research registered at Wilmington, Delaware, United States, is a global market research company providing custom research and consulting services. TMR provides in-depth insights into factors governing demand in the market. It divulges opportunities across various segments based on Source, Application, Sales Channel, and End-Use that will favor growth in the market over the next 9 years. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com Blog: https://tmrblog.com Email:sales@transparencymarketresearch.com

More Related